Safe Harbor Statement: Statements in this press release. Are not purely historical are forward, including statements regarding Peregrine Pharmaceuticals intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Financing statements include risks and including, but not including, but not is limited to, the risk that the company delays or difficulties in enrolling patients limited experience in the study, the risk that the standard carboplatin and paclitaxel response rate are not be improved the result the combination therapy and the risk that the results the subsequent stage for this study not consistent tadalafil 5mg canada . With the results of the first stage It is important to note that the company ‘s actual results may differ materially from those involve in such forward-looking statements Statements factors distinguish which may cause actual results to differ materially, may include, but are not limited to, uncertainties related to the completion of the preclinical and clinical trials for our technologies is severely restricted;. The early stage of product development, the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials, and obtaining additional funding reports development of our products support; obtaining regulatory approval for our technologies; winning anticipated timing of regulatory filings and the potential success of approval and compliance with governmental regulations for our business. Our business could be a number of other factors, including the risk factors listed from time to time be involved in the company ‘s SEC reports, including but not limited to, the Annual Report 30 on Form 10-K for the year ended April 2008 and the Quarterly Report on Form 10-Q for the quarter ended 31 October 2008. The company cautions investors not too heavily on the too heavily on the forward-looking statements in this news release. Peregrine Pharmaceuticals disclaims, any obligation and does not intend to update or revise forward-looking statements in this press release.
The Welsh Assembly Government has now decided to implement Early Support across all 22 local authorities in Wales. This Welsh Welsh local authorities and health authorities a package of Early Support materials and training to enable them to adopt the right kind of support for families. Continue reading